Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2
doses. To gain safety and efficacy data from a broader base of patients with HIV-associated
wasting in order to support Celgene's pivotal placebo-controlled study.